Korea Investment CORP Has $12.95 Million Stake in Agilent Technologies, Inc. $A

Key Points

• Korea Investment CORP cut its stake in Agilent by 54.4%, selling 120,179 shares and leaving it with 100,924 shares valued at about $12.95 million at quarter-end.
• Agilent announced strategic moves — agreeing to acquire Biocare Medical for ~$950 million and launching "Agilent Advanced Therapeutics" to scale CDMO services — aimed at boosting recurring consumables and higher‑margin service revenue.
• The company slightly missed quarterly expectations (EPS $1.36 vs. $1.37; revenue $1.80B vs. $1.81B), set FY2026 EPS guidance of 5.900–6.040, and declared a $0.255 quarterly dividend (annualized yield ~0.9%).

Korea Investment CORP reduced its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 54.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,924 shares of the medical research company's stock after selling 120,179 shares during the period. Korea Investment CORP's holdings in Agilent Technologies were worth $12,954,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in A. Capital A Wealth Management LLC boosted its stake in shares of Agilent Technologies by 10,600.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company's stock worth $25,000 after acquiring an additional 212 shares in the last quarter. Davis Capital Management bought a new position in shares of Agilent Technologies in the 3rd quarter valued at approximately $28,000. Physician Wealth Advisors Inc. lifted its holdings in Agilent Technologies by 490.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 236 shares of the medical research company's stock worth $30,000 after purchasing an additional 196 shares during the last quarter. State of Wyoming acquired a new stake in Agilent Technologies in the 2nd quarter worth approximately $35,000. Finally, SJS Investment Consulting Inc. boosted its position in Agilent Technologies by 2,836.4% during the third quarter. SJS Investment Consulting Inc. now owns 323 shares of the medical research company's stock worth $41,000 after purchasing an additional 312 shares during the period. Institutional investors and hedge funds own 87.41% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on A. HSBC began coverage on shares of Agilent Technologies in a research report on Tuesday, January 20th. They issued a "buy" rating and a $180.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Agilent Technologies in a research note on Tuesday, December 9th. They issued a "buy" rating and a $170.00 target price on the stock. Weiss Ratings reiterated a "hold (c+)" rating on shares of Agilent Technologies in a report on Monday, December 29th. Evercore raised shares of Agilent Technologies from an "in-line" rating to an "outperform" rating and boosted their target price for the stock from $155.00 to $160.00 in a research report on Monday, January 5th. Finally, Wells Fargo & Company decreased their price target on shares of Agilent Technologies from $175.00 to $165.00 and set an "overweight" rating for the company in a report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $161.20.

Agilent Technologies Stock Up 0.0%

Shares of A stock opened at $115.44 on Thursday. The stock has a market cap of $32.62 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $160.27. The stock has a fifty day moving average price of $131.36 and a 200 day moving average price of $135.93. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($0.01). Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. The business had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. During the same period last year, the firm earned $1.31 EPS. The company's quarterly revenue was up 7.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be paid a $0.255 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $1.02 dividend on an annualized basis and a yield of 0.9%. Agilent Technologies's payout ratio is presently 22.52%.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent agreed to acquire Biocare Medical for about $950 million — a bolt-on that strengthens its immunohistochemistry/diagnostics consumables and pathology market exposure, adding recurring reagents and slide/staining workflow products that can lift revenue durability and margin profile over time. Agilent to acquire Biocare in $950M 'complementary combination'
• Positive Sentiment: Agilent launched “Agilent Advanced Therapeutics,” unifying its CDMO capabilities across the U.S. and Canada — a move aimed at scaling drug-development and manufacturing services that can generate higher-margin service revenue and cross-sell opportunities with instrument/consumable customers. Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
• Neutral Sentiment: Citi opened a 90‑day “upside catalyst” watch on Agilent as part of a sector sweep — this flags potential positive catalysts but is not a formal upgrade; it signals analysts are watching for near‑term drivers rather than changing the fundamental view. Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
• Neutral Sentiment: Coverage noting “steady growth amid headwinds” emphasizes Agilent’s resilient top-line and reiterated FY26 guidance but highlights macro and sector pressures that could keep near-term multiples constrained. Agilent Technologies Signals Steady Growth Amid Headwinds
• Neutral Sentiment: Analysis pieces point out Agilent has recently underperformed the S&P 500 despite analyst optimism — a reminder that valuation and sector rotation dynamics could limit near-term upside. Is Agilent Technologies Stock Underperforming the S&P 500?
• Negative Sentiment: High-profile negative commentary from Jim Cramer — saying investors “don’t need” the stock — may pressure retail sentiment and contribute to short-term volatility despite the company’s strategic moves. Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.